Pancreatic Cancer Research

Clinical trialPhase 2Completed

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Clinical Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Outcome
Finished, no results posted
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
26 January 2018
Ended
28 February 2023
Enrollment
47 participants
Sites
1
Primary outcomes
The overall survival in this population of patients.
Sponsor type
Academic / other
Results posted
No
Last update
29 March 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug f Irinotecan,Oxaliplatin, and S1, with the goal of determining the OS of advanced pancreatic adenocarcinoma.. Subjects must have a newly diagnosed stage 4 untreated metastatic pancreatic ductal cancer and meet all inclusion/exclusion criteria. Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.